FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OIVID APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours por rosponso:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ESSIG STUART			<u> I</u>	2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS					(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 311 C ENTERPRISE DRIVE			3	CORP [IART] 3. Date of Earliest Transaction (Month/Day/Year) 12/18/2007						Officer (below)	(give title		Other (specify below)			
(Street) PLAINS (City)	BORO N	·	08536 (Zip)	_ -	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Inc Line)	K Form fil	oint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transc Date (Month/L			е	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Inst	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.			5. Amount Securities Beneficial Owned For Reported	Form lly (D) o ollowing (I) (In		n: Direct I or Indirect I nstr. 4) (7. Nature of ndirect Beneficial Ownership		
			Code V			Amount	(A) or (D)	Price	Transaction (Instr. 3 ar				(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ansaction Derivative Ex ode (Instr. Securities (M		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Non- Qualified Stock Option (right to buy)	\$40.34	12/18/2007		A		200,000		12/18/2007 ⁽¹⁾	12/18/2017	Common Stock	200,000	\$0.00	200,00	00	D	

Explanation of Responses:

 $1.\,25\%\ vests\ one\ year\ after\ the\ grant\ date\ of\ 12/18/2007\ and\ the\ remaining\ 75\%\ vests\ as\ follows:\ 1/36\ each\ month\ for\ the\ next\ 36\ months.$

Remarks

Power of attorney attached.

/s/ Kathryn Lamping, Attorney-

12/20/2007

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby authorizes Wilma Davis, Richard Gorelick, Kathryn Lamping and Richard Porter to execute for and on behalf of the undersigned Forms 3, 4 and 5, and any amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in Integra LifeSciences Holdings Corporation (the "Company"). The undersigned also authorizes the above persons to execute for and on behalf of the undersigned any Form ID or similar document required to obtain or renew Securities and Exchange Commission electronic filings codes and passwords and cause such form(s) to be submitted to and/or filed with the Securities and Exchange Commission. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of October, 2007.

/s/ Stuart Essig.

Print Name: Stuart Essig.